NCT04568798已完成不适用
Efficacy of Sana Treatment in Fibromyalgia: A Blinded Randomized Controlled Trial
Sana Health2 个研究点 分布在 1 个国家目标入组 166 人开始时间: 2020年7月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 166
- 试验地点
- 2
- 主要终点
- Change in quality of life as measured by the Revised Fibromyalgia Impact Questionnaire (FIQR).
研究概览
简要总结
The purpose of this research study is to evaluate the effectiveness of an experimental device called the Sana Pain Reliever Device (Sana Device) on treating pain due to fibromyalgia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing to and capable of providing written informed consent prior to the conduct of any study-related procedures.
- •Male or female, 18 to 65 years of age, inclusive.
- •Clinical diagnosis of Fibromyalgia given a minimum of 8 weeks prior to Screening.
- •Patient must have an average pain severity score of ≥40 and <90 on the 100-point VAS for the last 72 hours prior to Screening.
- •Any analgesic therapy must be at approximately stable levels for at least 14 days prior to enrollment and remain steady throughout the study.
- •Willing and able to comply with the study requirements, complete study assessments, and participate at scheduled times for the duration of the Treatment Phase.
- •Able to understand, speak and read English sufficient for the completion of study assessments.
排除标准
- •Pregnant or lactating females as self-reported.
- •History or presence of photo-sensitive epilepsy or other photo-sensitive conditions.
- •History or presence of condition(s) that may affect balance, such as seizure disorders or vertigo.
- •Diagnosis of cancer or active cancer treatment occurring within the last year.
- •Surgery or trauma requiring rehabilitation within the last 12 weeks.
- •Vision impairments that affect perception of light, color, or brightness in one or both eyes, and differences in visual perception between eyes, at the discretion of the investigator.
- •Deafness in one or both ears, perceived differences in hearing between ears, or tinnitus, at the discretion of the investigator.
- •Current ear or eye infection, untreated allergies, or acute illness that may affect eyes or hearing (e.g., due to congestion).
- •Presence of inflammation or broken skin around the eyes in the area of the mask.
- •Presence of narcolepsy or untreated sleep apnea or requiring treatment for sleep apnea such that use of device at bedtime will be interrupted, at discretion of the investigator.
- •Participation in any other clinical study in which medication(s) are being delivered or have used an investigational drug or device within the last 30 days.
- •Any pending legal action that could prohibit participation or compliance in the study.
- •Recent history of or current evidence of suicidal ideation or active suicidal behavior, based on medical history, at the discretion of the investigator.
- •Significant medical conditions or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study or obtaining informed consent, or may prevent the patient from safely participating in study.
结局指标
主要结局
Change in quality of life as measured by the Revised Fibromyalgia Impact Questionnaire (FIQR).
时间窗: Screening, Baseline, Days 14, 28, 56, 112 and 196.
Scores are measured on a 100 point scale (0-100) with the lower score (0) indicating no difficulty and the higher score indicating very difficult (100). Extreme Fibromyalgia (FM): 75-100, Severe FM: 60-74, Moderate FM: 43-59, Mild FM: 0-42
Change in health system utilization.
时间窗: Days 28 and 196.
Utilization is self reported via a Health Care Utilization survey.
次要结局
- Change in pain as measured by the Brief Pain Inventory (BPI).(Screening, Baseline, Days 14, 28, 56, 112 and 196.)
- Change in depression as measured by the Patient Health Questionnaire 8 (PHQ-8).(Screening, Baseline, Days 14, 28, 56, 112 and 196.)
- Change in anxiety as measured by the Generalized Anxiety Disorder 7 (GAD-7).(Screening, Baseline, Days 14, 28, 56, 112 and 196.)
- Change in sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI).(Screening, Baseline, Days 14, 28, 56, 112 and 196.)
- Change in pain as measured by the Pain Visual Analog Scale (P-VAS).(Daily (Day 0 - 196))
研究者
研究点 (2)
Loading locations...
相似试验
撤回
不适用
Effectiveness of the Sana Device on Fibromyalgia SymptomsPain, ChronicQuality of LifeFibromyalgiaNCT05394610Sana Health166
已完成
不适用
A New Rehabilitation Tool in FibromyalgiaPainFibromyalgiaNCT02472093University of Roma La Sapienza88
已完成
不适用
Self Soft Tissue Therapy for Fibromyalgia SyndromeFibromyalgia SyndromeNCT02881411University of the West of England20
已完成
不适用
Mollii Suit and Fibromyalgia (EXOFIB 2)Rheumatic DiseasesMuscular DiseasesNeuromuscular DiseasesNervous System DiseasesFibromyalgiaNCT06226376Sheikh Shakhbout Medical City28
已完成
2 期
Neurotropin Treatment of FibromyalgiaFibromyalgiaNCT00366535National Institute of Nursing Research (NINR)56